首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine
【24h】

Seasonal influenza infection and live vaccine prime for a response to the 2009 pandemic H1N1 vaccine

机译:季节性流感感染和活疫苗主要用于应对2009年H1N1大流行疫苗

获取原文
获取原文并翻译 | 示例
       

摘要

The robust immune response to a single dose of pandemic 2009 H1N1 vaccine suggests that a large segment of the population has been previously primed. We evaluated the effect of seasonal (s) H1N1 infection, s-trivalent inactivated vaccine (s-TIV), and trivalent s-live attenuated influenza vaccine (s-LAIV) before immunization with a pandemic live attenuated influenza vaccine (p-LAIV) in mice. We compared serum and mucosal antibody and pulmonary CD8 and CD4 responses and the virologic response to challenge with a wild-type 2009 pandemic H1N1 (p-H1 N1) virus. Two doses of p-LAIV induced cellular immune and robust ELISA and neutralizing antibody responses that were associated with complete protection from P-H1N1 challenge. A single dose of p-LAIV induced a cellular response and ELISA but not a neutralizing antibody response, and incomplete protection from p-H1N1 virus challenge. Primary infection with S-H1N1 influenza virus followed by a dose of p-LAIV resulted in cross-reactive ELISA antibodies and a robust cellular immune response that was also associated with complete protection from p-H1N1 virus challenge. A lower-magnitude but similar response associated with partial protection was seen in mice that received a dose of s-LAIV followed by p-LAIV. Mice that received a dose of s-TIV followed by p-LAIV did not show any evidence of priming. In summary, prior infection with a seasonal influenza virus or s-LAIV primed mice for a robust response to a single dose of p-LAIV that was associated with protection equivalent to two doses of the matched pandemic vaccine.
机译:对单剂大流行2009 H1N1疫苗的强劲免疫反应表明,以前有很大一部分人已经接种过这种疫苗。我们评估了季节性H1N1季节性感染,s-三价灭活疫苗(s-TIV)和三价s-活减毒流感疫苗(s-LAIV)的效果,然后再使用大流行减毒活流感疫苗(p-LAIV)进行免疫在小鼠中。我们比较了血清和粘膜抗体以及肺部CD8和CD4应答以及病毒学应答对野生型2009大流行H1N1(p-H1 N1)病毒的攻击。两剂p-LAIV诱导了细胞免疫和强大的ELISA并中和了抗体反应,这些反应与针对P-H1N1攻击的完全保护相关。单剂量的p-LAIV诱导细胞应答和ELISA,但不引起中和抗体应答,并且不能完全抵抗p-H1N1病毒攻击。初次感染S-H1N1流感病毒,然后注射一定剂量的p-LAIV导致交叉反应ELISA抗体和强大的细胞免疫应答,这也与对p-H1N1病毒攻击的完全保护相关。在接受一定剂量的s-LAIV,然后是p-LAIV的小鼠中,观察到较低的幅度但与部分保护相关的类似反应。接受一定剂量的s-TIV继之以p-LAIV的小鼠未显示任何致敏证据。总而言之,先前感染过季节性流感病毒或s-LAIV引发的小鼠对单剂量的p-LAIV有很强的反应,而p-LAIV的保护作用相当于两剂匹配的大流行疫苗。

著录项

  • 来源
  • 作者单位

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892,Medical Countermeasures (Biological) Laboratory, Defence Medical and Environmental Research Institute, DSO National Laboratories, Republic of Singapore 117510;

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;

    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892;

  • 收录信息 美国《科学引文索引》(SCI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 00:40:44

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号